Evaluation of AQUIOS STEM, a novel method for automated CD34+ stem cell enumeration using flow cytometry
Kim Callebaut1, Eva Gijbels2, Jonathan Vanbesien1
1AZ Delta Medical Laboratories, AZ Delta General Hospital, Roeselare, Belgium.
International Journal of Laboratory Hematology
|February 29, 2024
Summary
The AQUIOS STEM system accurately enumerates CD34+ hematopoietic progenitor cells (HPCs) for stem cell transplantation. This automated system shows excellent precision and stability, offering promising results for peripheral blood and fresh apheresis products.
Area of Science:
- Hematology
- Flow Cytometry
- Cellular Analysis
Background:
- Hematopoietic stem cell transplantation (HSCT) is a vital curative treatment for numerous diseases.
- Accurate enumeration of CD34+ cells is critical for optimizing stem cell collection and predicting engraftment.
- The AQUIOS STEM system offers a novel, automated solution for CD34+ cell enumeration.
Purpose of the Study:
- To evaluate the performance of the AQUIOS STEM system for CD34+ cell enumeration.
- To compare the AQUIOS STEM system with existing flow cytometry systems (FACSCanto-II, FACS Lyric).
- To assess analytical performance and clinical decision agreement across multiple centers.
Main Methods:
- Validation of the AQUIOS STEM system using 91 samples.
- Assessment of precision, sample stability, carryover, and linearity.
- Method comparison with current FACS systems for analytical and clinical agreement.
Main Results:
- Excellent precision with coefficients of variation <15% for quality control and patient samples.
- No significant carryover detected; fresh apheresis samples showed overnight stability.
- Good correlation in peripheral blood; minimal bias in fresh apheresis products, but lower correlation in cryopreserved products.
Conclusions:
- The AQUIOS CL system with STEM provides automated CD34+ stem cell enumeration.
- The system demonstrates strong analytical performance and positive outcomes for peripheral blood and fresh apheresis samples.
- This automated approach shows potential for reliable CD34+ cell quantification in clinical settings.


